Rapid Rx Quiz: Semaglutide

Mary L. Windle, PharmD


January 20, 2022

Semaglutide, specifically the brand Ozempic, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. It is also indicated to reduce risk for major adverse cardiovascular events (eg, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with T2D and established cardiovascular disease. Some patients may prefer oral administration (Rybelsus) over the subcutaneous form, and neither is recommended above the other.

Learn more about semaglutide for T2D.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.